Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips VYNE Therapeutics (NASDAQ: VYNE ) stock price predictions are heating up on Monday with one analyst setting a high goal for the company to reach. Source: luchschenF / Shutterstock.com H.C. Wainwright analyst J...
Shares in VYNE Therapeutics (VYNE +31.8%), a tiny biotech with a market cap of ~$62.6M, are surging today following a buy initiation from H.C. Wainwright. The firm has a $7 price target (669% return). Analyst Joseph Pantginis says that the company has a "reinvigorated" pipeline focused on ski...
Penny Stocks Insiders Decided To Buy This Month Who doesn’t like to take advantage of cheap prices? When it comes to penny stocks, compared to companies like Apple or Amazon, their prices may seem like they offer a steep discount. You also can’t forget that you’re a...
BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33 rd Annual Virtual Healthcare Conf...
The following slide deck was published by VYNE Therapeutics Inc. in conjunction with their 2021 Q3 earnings call. For further details see: VYNE Therapeutics Inc. 2021 Q3 - Results - Earnings Call Presentation
VYNE Therapeutics Inc. (VYNE) Q3 2021 Earnings Conference Call November 10, 2021, 08:30 AM ET Company Participants John Fraunces – LifeSci Advisors Dave Domzalski – President and Chief Executive Officer Tyler Zeronda – Chief Financiial Officer Iain Stuart – Chief S...
VYNE Therapeutics (NASDAQ:VYNE): Q3 Non-GAAP EPS of -$0.36 misses by $0.04; GAAP EPS of -$0.41 misses by $0.09. Revenue of $4.09M (+25.1% Y/Y) misses by $0.67M. Shares -0.74% PM. Press Release For further details see: VYNE Therapeutics EPS misses by $0.04, misses on revenue
Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sa...
VYNE Therapeutics (NASDAQ:VYNE) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is -$0.32 (-146.2% Y/Y) and the consensus Revenue Estimate is $4.76M (+45.6% Y/Y). Over the last 1 year, VYNE has beaten EPS estimates 100% ...
ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...